News

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...
AlphaGalileo6h
World-First Discovery of FLASH Effect Conditions Using Compact Carbon Ion Synchrotron Opens Door to Safer Cancer Therapy
A research team from The University of Osaka has made a significant breakthrough in cancer radiotherapy by identifying ...
The Manila Times18h
Explore the Future Growth - U.S. Battery Energy Storage Market to Hit $7.02 Billion by 2029!
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to ...
AlphaGalileo21h
Breakthrough Progress: New Inorganic Electro-Optic Materials May Pave the Way for 5G Communication
The Team from Huazhong University of Science and Technology Reveals the Electro-Optic Effect Mechanism and Future ...